Testing IAE0972 plus chemo for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a new drug called IAE0972 combined with chemotherapy for people with advanced head and neck cancer or nasopharyngeal cancer. It is for patients who have had limited prior treatment and are well enough to receive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with head and neck squamous cell carcinoma (in the mouth, throat, or voice box) or nasopharyngeal carcinoma that has spread or come back.
- You have had 2 or fewer prior treatments for your advanced cancer.
- You are healthy enough to receive chemotherapy.
- Your kidney, liver, and blood counts are within safe limits for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares different chemotherapy drugs given along with radiation therapy for people with locally advanced nasopharyngeal cancer. It aims to find which drug approach works better and is safer for this stage of disease.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of chemotherapy with two additional drugs (nimotuzumab and toripalimab) for people with advanced nasopharyngeal cancer that hasn't been treated yet. The goal is to see if this mix works better than standard therapy.
This trial tests a combination of two immune-based drugs (sintilimab and bevacizumab) plus standard chemotherapy for people with high-risk, locally advanced nasopharyngeal cancer that has spread to lymph nodes. The goal is to see if this approach works better than current treatments.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Hear when a new NPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.